These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 21216118)

  • 21. [A pilot study of peginterferon alfa-2a combined with short-term lamivudine therapy in HBeAg-positive chronic hepatitis B patients].
    Huang ZL; Zhao ZX; Deng H; Zhang YF; Lu CR; Gao ZL
    Zhonghua Gan Zang Bing Za Zhi; 2010 Jun; 18(6):419-22. PubMed ID: 20587310
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Quantifiable changes in HBeAg expression predict therapeutic efficacy of peg-interferon alfa-2a in patients with HBeAg-positive chronic hepatitis B].
    Ji YJ; Li FF; Ren WH; Zhu YH; Qin CY
    Zhonghua Gan Zang Bing Za Zhi; 2013 May; 21(5):335-9. PubMed ID: 24025132
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Early HBeAg loss during peginterferon alpha-2b therapy predicts HBsAg loss: results of a long-term follow-up study in chronic hepatitis B patients.
    Buster EH; Flink HJ; Simsek H; Heathcote EJ; Sharmila S; Kitis GE; Gerken G; Buti M; de Vries RA; Verhey E; Hansen BE; Janssen HL
    Am J Gastroenterol; 2009 Oct; 104(10):2449-57. PubMed ID: 19584831
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial.
    Janssen HL; van Zonneveld M; Senturk H; Zeuzem S; Akarca US; Cakaloglu Y; Simon C; So TM; Gerken G; de Man RA; Niesters HG; Zondervan P; Hansen B; Schalm SW; ;
    Lancet; 2005 Jan 8-14; 365(9454):123-9. PubMed ID: 15639293
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [A case report of treatment with pegylated interferon alpha for lamivudine-resistant chronic hepatitis B virus infection].
    Hur WH; Woo HY; Jeong SW; You CR; Bae SH; Choi JY; Yoon SK
    Korean J Hepatol; 2008 Dec; 14(4):513-8. PubMed ID: 19119246
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B.
    Lampertico P; Viganò M; Di Costanzo GG; Sagnelli E; Fasano M; Di Marco V; Boninsegna S; Farci P; Fargion S; Giuberti T; Iannacone C; Regep L; Massetto B; Facchetti F; Colombo M;
    Gut; 2013 Feb; 62(2):290-8. PubMed ID: 22859496
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improved efficacy by individualized combination therapy with Peg IFN-a 2a and ADV in HBeAg positive chronic hepatitis B patients.
    Wang YD; Zhao CY; Wang W; Shen C; Lu HZ; Zhang L; Yu WY; Zhou JY; Yan WZ
    Hepatogastroenterology; 2012 May; 59(115):680-6. PubMed ID: 22441104
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The safety of pegylated interferon alpha-2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinuation.
    van Zonneveld M; Flink HJ; Verhey E; Senturk H; Zeuzem S; Akarca US; Cakaloglu Y; Simon C; So TM; Gerken G; de Man RA; Hansen BE; Schalm SW; Janssen HL;
    Aliment Pharmacol Ther; 2005 May; 21(9):1163-71. PubMed ID: 15854180
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of pegylated interferon-alpha on the treatment of lamivudine resistant chronic HBeAg positive hepatitis B virus infection.
    Leemans WF; Flink HJ; Janssen HL; Niesters HG; Schalm SW; de Man RA
    J Hepatol; 2006 Mar; 44(3):507-11. PubMed ID: 16457904
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interferon and lamivudine combination therapy versus lamivudine monotherapy for hepatitis B e antigen-negative hepatitis B treatment: a meta-analysis of randomized controlled trials.
    Shi Y; Wu YH; Shu ZY; Zhang WJ; Yang J; Chen Z
    Hepatobiliary Pancreat Dis Int; 2010 Oct; 9(5):462-72. PubMed ID: 20943454
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination of pegylated interferon and lamivudine for patients with chronic hepatitis B who have failed treatment.
    Sarin SK; Kumar M; Hissar S; Sharma BC
    Hepatobiliary Pancreat Dis Int; 2006 Aug; 5(3):374-80. PubMed ID: 16911934
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A pilot study of extended duration peginterferon alfa-2a for patients with hepatitis B e antigen-negative chronic hepatitis B.
    Gish RG; Lau DT; Schmid P; Perrillo R
    Am J Gastroenterol; 2007 Dec; 102(12):2718-23. PubMed ID: 17662102
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and tolerability of pegylated interferon-α-2a in chronic hepatitis B: a multicenter clinical experience.
    Ratnam D; Dev A; Nguyen T; Sundararajan V; Harley H; Cheng W; Lee A; Rusli F; Chen R; Bell S; Pianko S; Sievert W
    J Gastroenterol Hepatol; 2012 Sep; 27(9):1447-53. PubMed ID: 22168789
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of thymosin α-1 plus peginterferon α-2a combination therapy compared with peginterferon α-2a monotherapy in HBeAg-positive chronic hepatitis B: a prospective, multicenter, randomized, open-label study.
    Kim BH; Lee YJ; Kim W; Yoon JH; Jung EU; Park SJ; Kim YJ; Lee HS
    Scand J Gastroenterol; 2012 Sep; 47(8-9):1048-55. PubMed ID: 22726105
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients.
    Sarin SK; Kumar M; Kumar R; Kazim SN; Guptan RC; Sakhuja P; Sharma BC
    Am J Gastroenterol; 2005 Nov; 100(11):2463-71. PubMed ID: 16279901
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B.
    Brunetto MR; Moriconi F; Bonino F; Lau GK; Farci P; Yurdaydin C; Piratvisuth T; Luo K; Wang Y; Hadziyannis S; Wolf E; McCloud P; Batrla R; Marcellin P
    Hepatology; 2009 Apr; 49(4):1141-50. PubMed ID: 19338056
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of hepatitis B with interferon and combination therapy.
    Cooksley WG
    Clin Liver Dis; 2004 May; 8(2):353-70. PubMed ID: 15481344
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modelling of early viral kinetics and pegylated interferon-alpha2b pharmacokinetics in patients with HBeag-positive chronic hepatitis B.
    ter Borg MJ; Hansen BE; Herrmann E; Zeuzem S; Cakaloglu Y; Karayalcin S; Flisiak R; van' t Veen A; de Man RA; Schalm SW; Janssen HL; Haagmans BL;
    Antivir Ther; 2007; 12(8):1285-94. PubMed ID: 18240868
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of chronic hepatitis B with the sequential administration of interferon and lamivudine.
    Hasan F; al-Khaldi J; Asker H; Varghese R; Siddique I; al-Shammali M; al-Kalaoui M; al-Nakib B
    Hepatogastroenterology; 2003; 50(54):2040-2. PubMed ID: 14696461
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline.
    Sonneveld MJ; Rijckborst V; Boucher CA; Hansen BE; Janssen HL
    Hepatology; 2010 Oct; 52(4):1251-7. PubMed ID: 20830787
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.